Last edition
News about "Rafal Kaminski"
Angelini Pharma, Quiver Bioscience Ink USD 120 Million Pact to Develop Genetic Epilepsy Therapies
Angelini Pharma and Quiver Bioscience have signed a multi-year collaboration to develop novel therapies for genetic epilepsies, combining AI-driven discovery tools with epilepsy expertise in a deal worth up to USD 120 million.
Rafal Kaminski | 25/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members